Metabolic acidosis recovers a wide range of diseases in which an oral alkalinization could be useful. This therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure. No prospective data has been published in clinical routine. Here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. The principal criterion of evaluation will be the variation in the extracellular compartment.
Metabolic acidosis recovers a wide range of diseases - chronic kidney diseases, nephrolithiasis, or others - in which an oral alkalinization could be useful. Oral alkalinization could be performed or by bicarbonate contained in alkaline-based waters or drug therapies or by citrate. This therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure, especially due to the amount of daily sodium load. No prospective data has been published in clinical routine, studying its effects on extracellular volume nor the blood pressure control. Here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. Initial recorded data will be: age, gender, prescription (indication, kind of alkali therapy, volume and duration), body weight, body length, a clinical appreciation of the extracellular compartment, blood pressure, comorbidities, drug therapy, blood and urine composition. The recorded follow-up will be: the adherence to treatment, body weight, body length, a clinical appreciation of the extracellular compartment, blood pressure, adverse events, blood and urine composition. The principal criterion of evaluation will be the variation in the extracellular compartment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
156
Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
Centre Hospitalier Pierre Oudot - Bourgoin-Jallieu
Bourgoin, France
La Cavale Blanche Hospital
Brest, France
CHMS Chambery
Chambéry, France
University Hospital of Grenoble
Grenoble, France
Calydial
Irigny, France
E.C.H.O. (Expansion des Centres d'Hémodialyse de l'Ouest)
Le Mans, France
La Conception University Hospital, AP-HM
Marseille, France
Institut Phocéen de Néphrologie, Clinique Bouchard
Marseille, France
Uninversity Hospital of Nantes
Nantes, France
AURA Paris Plaisance
Paris, France
...and 8 more locations
Extracellular compartment M3
Evaluation of the extracellular compartment by a composite clinical outcome at M3 composed by: body weight (kg), blood pressure (in mmHg, systolic and diastolic), and the presence edema
Time frame: At M3 (month 3)
Natremia (mM)
Evaluation of the impact of oral alkali therapy on natremia (mM)
Time frame: At M3 (month 3)
Urine output (l/d)
Evaluation of the impact of oral alkali therapy on urine output (l/d)
Time frame: At M3 (month 3)
Extracellular compartment M6
Evaluation of the extracellular compartment by a composite clinical outcome at M6 composed by: body weight (kg), blood pressure (in mmHg, systolic and diastolic), and the presence edema
Time frame: At M6 (month 6)
Kalemia (mM)
Evaluation of the impact of oral alkali therapy on kalemia (mM)
Time frame: At M3 (month 3)
Blood chloride (mM)
Evaluation of the impact of oral alkali therapy on blood chloride (mM)
Time frame: At M3 (month 3)
Bicarbonatemia (mM)
Evaluation of the impact of oral alkali therapy on bicarbonatemia (mM)
Time frame: At M3 (month 3)
Proteinemia (g/l)
Evaluation of the impact of oral alkali therapy on proteinemia (mM)
Time frame: At M3 (month 3)
Albuminemia (g/l)
Evaluation of the impact of oral alkali therapy on albuminemia (mM)
Time frame: At M3 (month 3)
Creatininemia (microM)
Evaluation of the impact of oral alkali therapy on creatininemia (mM)
Time frame: At M3 (month 3)
Natriuresis (mmol/d)
Evaluation of the impact of oral alkali therapy on natriuresis (mmol/d)
Time frame: At M3 (month 3)
Urine chloride (mmol/d)
Evaluation of the impact of oral alkali therapy on urine chloride (mmol/d)
Time frame: At M3 (month 3)
Proteinuria (g/d)
Evaluation of the impact of oral alkali therapy on proteinuria (g/d)
Time frame: At M3 (month 3)
Creatinuria (mmol/d)
Evaluation of the impact of oral alkali therapy on creatinuria (mmol/d)
Time frame: At M3 (month 3)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.